key: cord-0814736-wya9owt1 authors: Erlichster, M.; Chana, G.; Zantomio, D.; Goudey, B.; Skafidas, E. title: Utility of Pan-Family Assays for Rapid Viral Screening: Reducing Delays in Public Health Responses During Pandemics date: 2020-05-26 journal: nan DOI: 10.1101/2020.05.24.20112318 sha: 498e426b7a66e2aa517ccf340cc57f6cbbfa69e1 doc_id: 814736 cord_uid: wya9owt1 Background The SARS-CoV-2 pandemic has highlighted deficiencies in the testing capacity of many developed countries during the early stages of emerging pandemics. Here we describe the potential for pan-family viral assays to improve early accessibility of large-scale nucleic acid testing. Methods Coronaviruses and SARS-CoV-2 were used as a case-study for investigating the utility of pan-family viral assays during the early stages of a novel pandemic. Specificity of a pan-coronavirus (Pan-CoV) assay for viral detection was assessed using the frequency of common human coronavirus (HCoV) species in key populations. A reported Pan-CoV assay was assessed to determine sensitivity to SARS-CoV-2 and 59 other coronavirus species. The resilience of the primer target regions of this assay to mutation was assessed in 8893 high quality SARS-CoV-2 genomes to predict ongoing utility during pandemic progression. Findings Due to infection with common HCoV species, a Pan-CoV assay would return a false positive for as few as 1% of asymptomatic adults, but up to 30% of immunocompromised patients displaying symptoms of respiratory disease. Two of the four reported pan-coronavirus assays would have identified SARS-CoV-2 and we demonstrate that with small adjustments to the primers, these assays can accommodate novel variation observed in animal coronaviruses. The assay target region of one well established Pan-CoV assay is highly resistant to mutation compared to regions targeted by other widely applied SARS-CoV-2 RT-PCR assays. Interpretation Pan-family assays have the potential to greatly assist management of emerging public health emergencies through prioritization of high-resolution testing or isolation measures, despite limitations in test specificity due to cross-reactivity with common pathogens. Targeting highly conserved genomic regions make pan-family assays robust and resilient to mutation of a given virus. This approach may be applicable to other viral families and has utility as part of a strategic stockpile of tests maintained to better contain spread of novel diseases prior to the widespread availability of specific assays. . Current and proposed viral disease testing strategies. In the current strategy a 91 delay of weeks to months is observed between disease emergence and unrestricted testing, 92 allowing a disease to spread. By using pan-family tests widespread testing is available in a 93 shortened timeframe and disease spread may be contained. 94 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.24.20112318 doi: medRxiv preprint Specificity of a Pan-CoV assay to a novel pathogen -impact of endemic coronavirus 122 species 123 A key factor in the utility of pan-family assays is the frequency of common species of the target 124 family in the general population, as these will interfere with the specificity of an assay for the 125 novel pathogen. For the coronavirus family there are 4 endemic and common species that 126 infect humans (HCoV-229E, HCoV -NL63, HCoV-HKU1 and HCoV-OC43), typically 127 causing mild disease but can lead to severe or fatal infections in frail or immunosuppressed 128 patients. It remains to be seen whether the current SARS-CoV-2 pandemic will persist at low 129 levels in the general population following disease control through social distancing, therapeutic 130 measures or acquisition of herd immunity 13 . Non-endemic zoonotic coronavirus species 131 (SARS-CoV, MERS-CoV), while highly pathogenic, would not affect the specificity of a Pan-132 CoV assay for a novel pathogen as they are not observed at a relevant frequency. However, 133 Pan-CoV assay sensitivity to these pathogens is important as they are informative of species 134 with zoonotic potential. 135 136 Table 1 summarizes studies reporting the prevalence of common HCoV infection. HCoV 137 infections are typically detected in 2-10% of patients exhibiting acute respiratory illness (ARI), 138 although during local HCoV epidemics frequency of infection may be as high as 30% in 139 symptomatic patients. Additionally, HCoV infections display a seasonality, typically observed 140 in winter months. Children, both experiencing ARI and asymptomatic have a high occurrence 141 of HCoV infection (4-10%). In asymptomatic adults HCoV infection is less well studied, but 142 reported values are lower at ~1%. Studies of seroprevalence of HCoV antibodies indicate that 143 virtually all individuals have had prior exposure to at least one form of coronavirus, with first 144 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . exposure common in childhood 14 . This high frequency of childhood infection may explain the 145 lower prevalence of asymptomatic infection in adults due to a partial acquired immunity 15 , 146 though limited data exists describing the immunizing effect of HCoV infection 16 . 147 148 Considering the observed frequencies of common coronavirus species (Table 1) , a Pan-CoV 149 assay would be expected to be sufficiently specific for a novel pathogen to allow for broad 150 population screening, wherein a positive test is used to guide infection controls such as self-151 isolation. The screening specificity is strongest in asymptomatic adults where only ~1% of the 152 population would be expected to return a false positive due to HCoV infection. Greater caution 153 must be taken in populations with a higher HCoV infection rate such as children, symptomatic 154 patients with comorbidities, or populations experiencing a local HCoV epidemic. Due to 155 relatively high frequency of common HCoV infection in these populations additional follow 156 up testing may be necessary to improve the utility to public health officials. 157 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 26, 2020. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.24.20112318 doi: medRxiv preprint Sensitivity of Pan-CoV assays to a novel pathogen -performance of reported assays on 160 observed coronavirus species from animal populations 161 Several consensus reverse-transcription PCR (RT-PCR) assays targeting the highly conserved 162 coronavirus RNA-dependent RNA polymerase gene with a pool of degenerate primers have 163 been previously described for research applications 6-9 . These assays have been used to identify 164 and analyze previously unknown coronavirus species 3 and perform retrospective analysis of 165 clinical samples to assess disease prevalence 20 . 166 CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.24.20112318 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.24.20112318 doi: medRxiv preprint In contrast to the other reported Pan-COV assays, the Moes/Vijgen assay (MPC) has a detailed 181 protocol for analysis of respiratory pathogens in human samples 7 . To better predict the 182 sensitivity of this assay to novel pathogens, we compared the MPC primer sequences to the 183 respective primer target sites in the genomes of 60 coronavirus species (supplementary Table 184 2). The majority of these species were reported following the development of the MPC assay, 185 and as such are informative of the capacity of existing tests to detect novel pathogens. 186 Of the 60 coronavirus reference sequences investigated, 20 contained a mismatch between the 188 MPC degenerate primer target and the viral genome, suggesting the MPC assay would be sub-189 optimal for detection of these species (Figure 3, CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.24.20112318 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.24.20112318 doi: medRxiv preprint Another application of a robust pan-family assay is as a fallback to protect against reduction in 206 test sensitivity of species-specific assays due to mutation of the viral pathogen during pandemic 207 progression. To assess the resilience of the MPC assay to mutation-derived errors, we assessed 208 mutation frequency of the MPC target sites in 8,893 high-coverage SARS-CoV-2 genomes. 209 Only a single sample with a mutation in the MPC target region was observed, 210 EPI_ISL_414596, translating to an observed mutation rate of 0.01%. This is an order of 211 magnitude lower than the observed mutation rate for the CDC primer regions (0.4-2.58%) and 212 the China CDC primer regions (0.74-16.19%) in the same dataset as reported on the GISAID 213 platform 11 . These results indicate that the MPC target region is robust to mutation and may 214 provide ongoing value in the case of emergence of a viral strain with mutations in the target 215 regions of high specificity assays. 216 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.24.20112318 doi: medRxiv preprint Nucleic acid testing for the identification of infected individuals is one the most valuable tools 218 for controlling pathogen spread, especially for diseases with asymptomatic carriers. The recent 219 SARS-CoV-2 pandemic has revealed deficiencies in the testing capacity of many countries, 220 resulting in a period where testing was highly restricted, preventing optimal disease 221 containment. The use of family-wide viral assays may reduce the time before mass testing is 222 available by allowing tests to be developed and distributed before pathogen emergence. Here 223 we demonstrate that a Pan-CoV test can be an effective tool for management of novel 224 coronavirus pathogens. These results may also be more broadly applicable for the 225 implementation of pan-family assays for the detection of pathogens from other viral families. 226 Table 2 summarizes the advantages and disadvantages of a Pan-family assay compared with 227 the current high-specificity testing standard approach. 228 229 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. -Stockpiling prior to pandemic development enables rapid and extensive population screening. -Validated and quality controlled prior to pandemic development -Can prioritize individuals for testing with short-supply Specific Virus Assays. -Susceptible to off-target positives due to cross-reactivity with common pathogens, reducing diagnostic value or mandating follow up testing. -Sensitivity and specificity of testing dependent on viral family and population of interest. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.24.20112318 doi: medRxiv preprint Coronaviruses are a useful framework for assessing the utility of pan-family testing as several 232 human coronaviruses are common globally and would interfere with specific identification of 233 a novel coronavirus pathogen. However, even without any further testing a Pan-CoV test still 234 allows for a large majority (>90%) of individuals, particularly asymptomatic adults, to avoid 235 self-isolation measures with a negative test, though greater caution must be taken in 236 populations with a higher HCoV infection rate such as children, symptomatic patients with 237 comorbidities, or populations experiencing a local HCoV epidemic. This limitation can be 238 mitigated through multiple strategies, most simply application of this tool as a first-line screen 239 prior to confirmatory analysis with a more specific test. This would allow short-supply specific 240 tests to be reserved as a confirmatory, rather than a primary tool, enabling a higher-throughput 241 screen of large populations at ports-of-entry or for contact tracing during the early stages of 242 pandemic. An alternative strategy, not reliant on the presence of a specific test, would be the 243 addition of a second exclusionary reaction targeting known common species 30 , though this may 244 not be an effective tool where a novel pathogen is highly genetically similar to a common 245 species and may be overly burdensome for high-throughput population screening. 246 247 During the initial roll-out of SARS-CoV-2 testing kits by the CDC, several laboratories 248 experienced disruptions due to faulty testing kits 31 . Pan-family assays, developed prior to an 249 outbreak, would have a relaxed timeframe for test development, ensuring best-practice 250 validation, quality control procedures, regulatory certification and laboratory accreditation can 251 be achieved. Pan-family assays may also have additional ongoing utility as a fallback in the 252 case of quality control issues or disease mutations compromising the accuracy of specific assay 253 detection 32 . By targeting highly conserved regions and accommodating silent mutations, pan-254 family assays can be expected to be less prone to mutation induced errors, though routine 255 comparison of primer target sites with observed viral strains is prudent. Further consideration 256 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.24.20112318 doi: medRxiv preprint must be given to the appropriate number of targets contained in a pan-family test to increase 257 the likelihood that a novel pathogen is captured by an established assay, as well as the 258 appropriate validation processes which should be undertaken following pathogen emergence 259 before the approved use of a pan-family assay. and production volume can be expected to cost below 0.5USD/test, with a shelf life of at least 294 2 years. However, to increase the simplicity and rapidity of testing it may be practical to 295 stockpile all reagents required to run a pan-family assay as part of a self-contained test-kit, 296 despite the additional cost. 297 298 Strategic stockpiling of pan-family viral assays is a proactive alternative to current viral disease 299 test strategies which may expedite testing during emerging pandemics. These assays have the 300 potential to greatly assist management of emerging public health emergencies through 301 prioritization of high-resolution testing or isolation measures, despite limitations in test 302 specificity due to cross-reactivity with common pathogens. Extensive further development, 303 validation and certification of pan-family assays is needed prior to application in broad clinical 304 contexts. With appropriate design these tools may allow informative and high-throughput 305 screening of millions of individuals within days of pathogen emergence. 306 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 26, 2020. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 26, 2020. . SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. RT-PCR assay Virus Variation Resource -improved response to emergent viral 345 outbreaks Phylogenetic analysis of a highly Epidemiological and clinical features of human Detection of the Human Coronavirus 229E, HKU1, NL63, and OC43 393 between 2010 and 2013 in Yamagata Burden of respiratory syncytial virus infections in China: Systematic review 396 and meta-analysis A six-year descriptive epidemiological study of human coronavirus infections 398 in hospitalized patients in Hong Kong Prevalence and genetic diversity analysis of human coronaviruses among cross-400 border children Epidemiology and clinical characteristics of human coronaviruses OC43 Human coronavirus circulation in the United States Human Coronavirus in Hospitalized Children With Respiratory Tract 408 Infections: A 9-Year Population-Based Study From Norway The effect of primer-template mismatches on the detection and 411 quantification of nucleic acids using the 5′ nuclease assay A Melting Curve-Based Multiplex RT-qPCR Assay for Simultaneous Detection 414 of Four Human Coronaviruses Thousands of coronavirus tests are going unused in US labs Potential preanalytical and analytical 418 vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19) 5-Nitroindole as an universal base analogue Supplementary